Holen Sie sich die Stockscreener-App
23.16
1.94%
0.44
Handel nachbörslich:
23.16
Schlusskurs vom Vortag:
$22.72
Offen:
$22.97
24-Stunden-Volumen:
486.50K
Relative Volume:
0.91
Marktkapitalisierung:
$1.52B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-137.95M
KGV:
-9.181
EPS:
-2.5226
Netto-Cashflow:
$-107.11M
1W Leistung:
+5.66%
1M Leistung:
+7.87%
6M Leistung:
+63.79%
1J Leistung:
+65.43%
1-Tages-Spanne:
$22.21
$23.19
1-Wochen-Bereich:
$21.07
$23.19
52-Wochen-Spanne:
$7.80
$24.25
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Firmenname
Bicara Therapeutics Inc
Sektor
Branche
Telefon
617-468-4219
Adresse
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Compare BCAX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
23.16 | 1.49B | 0 | -137.95M | -107.11M | -2.5226 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-25 | Eingeleitet | BofA Securities | Buy |
| 2026-01-29 | Eingeleitet | Citizens JMP | Mkt Perform |
| 2026-01-08 | Eingeleitet | BTIG Research | Buy |
| 2025-12-18 | Eingeleitet | Mizuho | Neutral |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-05-23 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2025-04-17 | Eingeleitet | Wells Fargo | Underweight |
| 2025-02-06 | Eingeleitet | Wedbush | Outperform |
| 2024-12-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-05 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-10-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-08 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-10-08 | Eingeleitet | Stifel | Buy |
| 2024-10-08 | Eingeleitet | TD Cowen | Buy |
Alle ansehen
Bicara Therapeutics Inc Aktie (BCAX) Neueste Nachrichten
Bicara Therapeutics Chief Medical Officer Sells 5,500 Shares for $126,000 - AOL.com
Claire Mazumdar: A silent force behind a $1.6 billion firm may write Biocon's future scripts - The Economic Times
Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET - The Manila Times
Bicara Therapeutics Inc. schedules May 11 conference for first quarter 2026 financial results - Traders Union
Bicara posts Q1 results May 11, with business update before market - Stock Titan
Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) Insider Sells 5,500 Shares of Stock - MarketBeat
Bicara Therapeutics CMO David Raben sells $125,830 in shares By Investing.com - Investing.com Canada
Bicara Therapeutics CMO David Raben sells $125,830 in shares - Investing.com
Bicara Therapeutics (BCAX) CMO sells 5,500 shares after option exercise - Stock Titan
BCAX SEC FilingsBicara Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
5,500-share sale planned by BCAX (BCAX) via Form 144 on 04/27/2026 - Stock Titan
Wall Street Analysts Believe Bicara Therapeutics Inc. (BCAX) Could Rally 54.85%: Here's is How to Trade - MSN
Bicara Therapeutics (BCAX) details 2026 vote on directors and KPMG - Stock Titan
Certain Stock Option of Bicara Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 26-APR-2026. - marketscreener.com
BCAX (Bicara Therapeutics Inc.) posts narrow Q4 2025 EPS beat, shares tick higher following its quarterly earnings announcement.Social Momentum Signals - UBND thành phố Hải Phòng
Bicara Therapeutics CFO Hyep sells $211k in stock By Investing.com - Investing.com South Africa
Bicara Therapeutics CFO Hyep sells $211k in stock - Investing.com
Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) CFO Sells 9,200 Shares of Stock - MarketBeat
[Form 4] Bicara Therapeutics Inc. Insider Trading Activity - Stock Titan
BCAX (BCAX) Form 144 shows option exercise and multiple insider sales - Stock Titan
Bicara Therapeutics (NASDAQ:BCAX) CEO Claire Mazumdar Sells 15,000 Shares - MarketBeat
Bicara Therapeutics CEO Mazumdar sells $354k in stock By Investing.com - Investing.com Canada
Bicara Therapeutics CEO Mazumdar sells $354k in stock - Investing.com
Bicara Therapeutics (BCAX) CEO sells 15K shares, exercises 37,760 options - Stock Titan
BCAX (BCAX) notice: 15,000 shares to be sold after option exercise - Stock Titan
Bicara Therapeutics stock hits 52-week high at 24.14 USD By Investing.com - Investing.com India
Cohlhepp Ryan, president and COO of Bicara, sells $287k in BCAX stock - Investing.com India
Bicara Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) COO Sells 12,500 Shares of Stock - MarketBeat
Bicara Therapeutics (BCAX) president exercises options and sells 12,500 shares - Stock Titan
Bicara Therapeutics stock hits 52-week high at 24.14 USD - Investing.com
Bicara Therapeutics Inc. (BCAX) Stock Analysis: Assessing a 27% Upside Potential for this Biotech Innovator - DirectorsTalk Interviews
Insider sales and option exercises reported for BCAX (NASDAQ: BCAX) - Stock Titan
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Reaches New 52-Week HighTime to Buy? - MarketBeat
History Review: Is Bicara Therapeutics Incs growth already priced inOptions Play & Technical Buy Zone Confirmation - baoquankhu1.vn
CEO Moves: How liquid is Bicara Therapeutics Inc stockWeekly Risk Report & Free Reliable Trade Execution Plans - baoquankhu1.vn
BCAX PE Ratio & Valuation, Is BCAX Overvalued - Intellectia AI
Published on: 2026-04-10 20:40:14 - baoquankhu1.vn
Trading Recap: How is Bicara Therapeutics Inc managing supply chain issues2026 Retail & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Bicara Therapeutics stock hits 52-week high at 21.99 USD By Investing.com - Investing.com Australia
Finanzdaten der Bicara Therapeutics Inc-Aktie (BCAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):